<meta http-equiv="Content-Type" content="text/html; charset=utf-8"><link type="text/css" rel="stylesheet" href="resources/sheet.css" >
<style type="text/css">.ritz .waffle a { color: inherit; }.ritz .waffle .s10{border-left: none;background-color:#ffffff;}.ritz .waffle .s9{border-left: none;border-right: none;background-color:#ffffff;text-align:left;font-weight:bold;color:#000000;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:nowrap;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s8{border-right: none;background-color:#ffffff;text-align:left;color:#000000;font-family:'docs-Roboto',Arial;font-size:10pt;vertical-align:bottom;white-space:nowrap;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s1{border-left: none;border-right: none;background-color:#ffffff;}.ritz .waffle .s7{border-left: none;background-color:#ffffff;text-align:left;color:#000000;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:nowrap;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s2{background-color:#ffffff;text-align:left;color:#000000;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:nowrap;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s3{border-right: none;background-color:#ffffff;text-align:left;color:#000000;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:nowrap;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s0{border-right: none;background-color:#ffffff;text-align:left;font-weight:bold;text-decoration:underline;-webkit-text-decoration-skip:none;text-decoration-skip-ink:none;color:#000000;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:nowrap;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s11{border-right: none;background-color:#ffffff;text-align:left;text-decoration:underline;-webkit-text-decoration-skip:none;text-decoration-skip-ink:none;color:#000000;font-family:'docs-Libre Franklin',Arial;font-size:8pt;vertical-align:bottom;white-space:nowrap;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s5{background-color:#ffffff;text-align:left;font-weight:bold;color:#000000;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:nowrap;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s4{border-left: none;border-right: none;background-color:#ffffff;text-align:left;color:#000000;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:nowrap;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s12{border-right: none;background-color:#ffffff;text-align:left;text-decoration:underline;-webkit-text-decoration-skip:none;text-decoration-skip-ink:none;color:#000000;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:nowrap;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s6{border-right: none;background-color:#ffffff;text-align:left;font-weight:bold;color:#000000;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:nowrap;direction:ltr;padding:2px 3px 2px 3px;}</style><div class="ritz grid-container" dir="ltr"><table class="waffle" cellspacing="0" cellpadding="0"><thead><tr><th class="row-header freezebar-origin-ltr"></th><th id="1856240103C0" style="width:100px;" class="column-headers-background">A</th><th id="1856240103C1" style="width:100px;" class="column-headers-background">B</th></tr></thead><tbody><tr style="height: 20px"><th id="1856240103R0" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">1</div></th><td class="s0 softmerge" dir="ltr"><div class="softmerge-inner" style="width:398px;left:-1px">Red Cell Antibodies / Anti-D / Rhesus / Kleihauer</div></td><td class="s1"></td></tr><tr style="height: 20px"><th id="1856240103R1" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">2</div></th><td class="s2" dir="ltr"></td><td class="s2" dir="ltr"></td></tr><tr style="height: 20px"><th id="1856240103R2" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">3</div></th><td class="s3 softmerge" dir="ltr"><div class="softmerge-inner" style="width:698px;left:-1px">Red cell antibodies are important as they may cause severe fetal anaemia and lead to poor neonate outcomes.</div></td><td class="s4" dir="ltr"></td></tr><tr style="height: 20px"><th id="1856240103R3" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">4</div></th><td class="s2" dir="ltr"></td><td class="s2" dir="ltr"></td></tr><tr style="height: 20px"><th id="1856240103R4" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">5</div></th><td class="s5" dir="ltr">Antibody titre</td><td class="s6 softmerge" dir="ltr"><div class="softmerge-inner" style="width:598px;left:-1px">Level at which patient should be referred to fetal medicine specialist (iu/ml)</div></td></tr><tr style="height: 20px"><th id="1856240103R5" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">6</div></th><td class="s2" dir="ltr">Anti-D</td><td class="s2" dir="ltr">&gt;4</td></tr><tr style="height: 20px"><th id="1856240103R6" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">7</div></th><td class="s2" dir="ltr">Anti-C</td><td class="s2" dir="ltr">&gt;7.5</td></tr><tr style="height: 20px"><th id="1856240103R7" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">8</div></th><td class="s2" dir="ltr">Anti-K</td><td class="s3 softmerge" dir="ltr"><div class="softmerge-inner" style="width:198px;left:-1px">Refer if detected</div></td></tr><tr style="height: 20px"><th id="1856240103R8" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">9</div></th><td class="s2" dir="ltr">Anti-E</td><td class="s3 softmerge" dir="ltr"><div class="softmerge-inner" style="width:298px;left:-1px">Refer if anti-C antibodies present</div></td></tr><tr style="height: 20px"><th id="1856240103R9" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">10</div></th><td class="s2" dir="ltr"></td><td class="s2" dir="ltr"></td></tr><tr style="height: 20px"><th id="1856240103R10" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">11</div></th><td class="s6 softmerge" dir="ltr"><div class="softmerge-inner" style="width:298px;left:-1px">Monitoring after referral level triggered</div></td><td class="s4" dir="ltr"></td></tr><tr style="height: 20px"><th id="1856240103R11" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">12</div></th><td class="s3 softmerge" dir="ltr"><div class="softmerge-inner" style="width:498px;left:-1px">Weekly fetal middle cerebral artery peak systolic velocities (MCA PSV)</div></td><td class="s4" dir="ltr"></td></tr><tr style="height: 20px"><th id="1856240103R12" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">13</div></th><td class="s3 softmerge" dir="ltr"><div class="softmerge-inner" style="width:798px;left:-1px">MCA PSV above 1.5 multiples of the median then refer back to fetal medicine specialist for consideration invasive treatment</div></td><td class="s4" dir="ltr"></td></tr><tr style="height: 20px"><th id="1856240103R13" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">14</div></th><td class="s2" dir="ltr"></td><td class="s2" dir="ltr"></td></tr><tr style="height: 20px"><th id="1856240103R14" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">15</div></th><td class="s6 softmerge" dir="ltr"><div class="softmerge-inner" style="width:198px;left:-1px">Monitoring Frequency</div></td><td class="s7" dir="ltr"></td></tr><tr style="height: 20px"><th id="1856240103R15" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">16</div></th><td class="s3 softmerge" dir="ltr"><div class="softmerge-inner" style="width:498px;left:-1px">Anti C,D and K levels every 4 weeks until 28 weeks then every 2 weeks until delivery</div></td><td class="s4" dir="ltr"></td></tr><tr style="height: 20px"><th id="1856240103R16" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">17</div></th><td class="s3 softmerge" dir="ltr"><div class="softmerge-inner" style="width:1198px;left:-1px">If a patient has red cell antibodies and other pathologies that make them high risk for transfusion e.g. placenta previae or sickle cell disease then they should have a cross-match performed every week.</div></td><td class="s4" dir="ltr"></td></tr><tr style="height: 20px"><th id="1856240103R17" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">18</div></th><td></td><td></td></tr><tr style="height: 20px"><th id="1856240103R18" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">19</div></th><td class="s6 softmerge" dir="ltr"><div class="softmerge-inner" style="width:298px;left:-1px">At delivery for red cell autoantibodies</div></td><td class="s1"></td></tr><tr style="height: 20px"><th id="1856240103R19" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">20</div></th><td class="s3 softmerge" dir="ltr"><div class="softmerge-inner" style="width:598px;left:-1px">Additional cord samples: Direct antiglobulin test (DAT), haemoglobin and bilirubin levels</div></td><td class="s1"></td></tr><tr style="height: 20px"><th id="1856240103R20" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">21</div></th><td class="s3 softmerge" dir="ltr"><div class="softmerge-inner" style="width:398px;left:-1px">Red cell antibodies pose a risk of haemolytic anaemia. </div></td><td class="s1"></td></tr><tr style="height: 20px"><th id="1856240103R21" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">22</div></th><td class="s8 softmerge" dir="ltr"><div class="softmerge-inner" style="width:1498px;left:-1px">Additional tests are directed at checking for immune reaction (DAT - detects immunoglobulin/complement coating RBCs) and anaemia (directly through haemoglobin and indirectly through bilirubin which is a byproduct of red cell breakdown).</div></td><td class="s1"></td></tr><tr style="height: 20px"><th id="1856240103R22" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">23</div></th><td class="s3 softmerge" dir="ltr"><div class="softmerge-inner" style="width:898px;left:-1px">In addition to the dangers anaemia can pose to the neonate, build up of bilirubin can lead to Kernicterus (bilirubin induced brain dysfunction).</div></td><td class="s1"></td></tr><tr style="height: 20px"><th id="1856240103R23" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">24</div></th><td class="s5" dir="ltr"></td><td></td></tr><tr style="height: 20px"><th id="1856240103R24" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">25</div></th><td class="s6 softmerge" dir="ltr"><div class="softmerge-inner" style="width:298px;left:-1px">Rhesus Isoimmunisation Key Points</div></td><td class="s1"></td></tr><tr style="height: 20px"><th id="1856240103R25" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">26</div></th><td class="s3 softmerge" dir="ltr"><div class="softmerge-inner" style="width:1098px;left:-1px">Refers to immune response when a women who does not have rhesus antigens on her red cells (Rhesus negative) is exposed to red cells that have the Rhesus antigen (Rhesus positive)</div></td><td class="s1"></td></tr><tr style="height: 20px"><th id="1856240103R26" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">27</div></th><td class="s3 softmerge" dir="ltr"><div class="softmerge-inner" style="width:598px;left:-1px">Occurs when father of fetus is rhesus positive resulting in the fetus having Rhesus positive blood</div></td><td class="s1"></td></tr><tr style="height: 20px"><th id="1856240103R27" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">28</div></th><td class="s3 softmerge" dir="ltr"><div class="softmerge-inner" style="width:698px;left:-1px">Once sensitised the mother may develop antibodies (IgG) to the fetal blood which can cross the placenta</div></td><td class="s1"></td></tr><tr style="height: 20px"><th id="1856240103R28" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">29</div></th><td class="s3 softmerge" dir="ltr"><div class="softmerge-inner" style="width:698px;left:-1px">Antibody reaction can lead to mild anaemia, haemolytic disease of the newborn (HDN ) or even fetal death</div></td><td class="s1"></td></tr><tr style="height: 20px"><th id="1856240103R29" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">30</div></th><td class="s3 softmerge" dir="ltr"><div class="softmerge-inner" style="width:598px;left:-1px">Typically occurs in pregnancy subsequent to the one where the mother becomes sensitised</div></td><td class="s1"></td></tr><tr style="height: 20px"><th id="1856240103R30" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">31</div></th><td class="s3 softmerge" dir="ltr"><div class="softmerge-inner" style="width:1198px;left:-1px">Rho(D) immune globulin or Anti-D is a solution of IgG antibodies that can bind to any Rh positive blood that may have entered the maternal blood stream and prevent a maternal immune reaction</div></td><td class="s1"></td></tr><tr style="height: 20px"><th id="1856240103R31" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">32</div></th><td class="s3 softmerge" dir="ltr"><div class="softmerge-inner" style="width:698px;left:-1px">The use of anti-D has reduced the risk of allommunisation of Rh negative mothers from 16% to as low as 0.1%.</div></td><td class="s1"></td></tr><tr style="height: 20px"><th id="1856240103R32" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">33</div></th><td class="s2" dir="ltr"></td><td></td></tr><tr style="height: 20px"><th id="1856240103R33" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">34</div></th><td class="s6 softmerge" dir="ltr"><div class="softmerge-inner" style="width:298px;left:-1px">Anti-D Ig Key Points from BCSH Guidelines*</div></td><td class="s9"></td></tr><tr style="height: 20px"><th id="1856240103R34" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">35</div></th><td class="s3 softmerge" dir="ltr"><div class="softmerge-inner" style="width:1498px;left:-1px">All RhD negative pregnant women who have not been previously sensitised should be offered routine antenatal prophylaxis with anti-D Ig (RAADP) either with a single dose regimen at around 28weeks, or two-dose regimen given at 28 and 34weeks</div></td><td class="s1"></td></tr><tr style="height: 20px"><th id="1856240103R35" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">36</div></th><td class="s3 softmerge" dir="ltr"><div class="softmerge-inner" style="width:1998px;left:-1px">Following birth, ABO and Rh D typing should be performed on cord blood and if the baby is confirmed to be D positive, all D negative, previously non-sensitised, women should be offered at least 500 IU of anti-D Ig within 72h following delivery. Maternal samples should be tested for FMH and additional dose(s) given as guided by FMH tests</div></td><td class="s1"></td></tr><tr style="height: 20px"><th id="1856240103R36" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">37</div></th><td class="s3 softmerge" dir="ltr"><div class="softmerge-inner" style="width:1598px;left:-1px">Following potentially sensitising events, anti-D Ig should be administered as soon as possible and always within 72h of the event. If, exceptionally, this deadline has not been met some protection may be offered if anti-D Ig is given up to 10days after the sensitising event</div></td><td class="s1"></td></tr><tr style="height: 20px"><th id="1856240103R37" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">38</div></th><td class="s3 softmerge" dir="ltr"><div class="softmerge-inner" style="width:2198px;left:-1px">In pregnancies &lt;12 weeks gestation, anti-D Ig prophylaxis is only indicated following ectopic pregnancy, molar pregnancy, therapeutic termination of pregnancy and in cases of uterine bleeding where there is repeated, heavy bleeding or associated with abdominal pain. The minimum dose should be 250 IU. A test for fetomaternal haemorrhage (FMH) is not required</div></td><td class="s1"></td></tr><tr style="height: 20px"><th id="1856240103R38" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">39</div></th><td class="s3 softmerge" dir="ltr"><div class="softmerge-inner" style="width:1098px;left:-1px">For potentially sensitising events between 12 and 20 weeks gestation, a minimum dose of 250 IU should be administered within 72h of the event. A test for FMH is not required</div></td><td class="s1"></td></tr><tr style="height: 20px"><th id="1856240103R39" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">40</div></th><td class="s3 softmerge" dir="ltr"><div class="softmerge-inner" style="width:998px;left:-1px">For potentially sensitising events after 20 weeks gestation, a minimum anti-D Ig dose of 500 IU should be administered within 72h of the event. A test for FMH is required</div></td><td class="s1"></td></tr><tr style="height: 20px"><th id="1856240103R40" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">41</div></th><td class="s3 softmerge" dir="ltr"><div class="softmerge-inner" style="width:998px;left:-1px">A dose of 500 IU, IM is considered sufficient to treat a FMH of up to 4mL fetal red cells. Additional anti-D Ig doses calculated as 125 IU anti-D Ig/mL fetal red cells (IM)</div></td><td class="s1"></td></tr><tr style="height: 20px"><th id="1856240103R41" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">42</div></th><td></td><td></td></tr><tr style="height: 20px"><th id="1856240103R42" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">43</div></th><td class="s5" dir="ltr">Other Issues</td><td></td></tr><tr style="height: 20px"><th id="1856240103R43" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">44</div></th><td class="s3 softmerge" dir="ltr"><div class="softmerge-inner" style="width:598px;left:-1px">It is not necessary to administer anti-D Ig to D negative females without childbearing potential</div></td><td class="s1"></td></tr><tr style="height: 20px"><th id="1856240103R44" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">45</div></th><td class="s3 softmerge" dir="ltr"><div class="softmerge-inner" style="width:798px;left:-1px">A dose of 250 IU anti-D immunoglobulin should be sufficient to cover up to five adult therapeutic doses of D-positive platelets</div></td><td class="s1"></td></tr><tr style="height: 20px"><th id="1856240103R45" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">46</div></th><td class="s3 softmerge" dir="ltr"><div class="softmerge-inner" style="width:398px;left:-1px">If Rh+ve blood has been transfused there are 2 thresholds:</div></td><td class="s1"></td></tr><tr style="height: 20px"><th id="1856240103R46" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">47</div></th><td class="s3 softmerge" dir="ltr"><div class="softmerge-inner" style="width:298px;left:-1px">&gt;15ml: give 1500 or 2500 IU anti-D ig</div></td><td class="s1"></td></tr><tr style="height: 20px"><th id="1856240103R47" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">48</div></th><td class="s3 softmerge" dir="ltr"><div class="softmerge-inner" style="width:298px;left:-1px">&gt;1 unit: arrange red cell exchange transfusion</div></td><td class="s1"></td></tr><tr style="height: 20px"><th id="1856240103R48" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">49</div></th><td class="s5" dir="ltr"></td><td></td></tr><tr style="height: 20px"><th id="1856240103R49" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">50</div></th><td class="s6 softmerge" dir="ltr"><div class="softmerge-inner" style="width:298px;left:-1px">List of Potentially Sensitising Events</div></td><td class="s1"></td></tr><tr style="height: 20px"><th id="1856240103R50" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">51</div></th><td class="s3 softmerge" dir="ltr"><div class="softmerge-inner" style="width:398px;left:-1px">Amniocentesis, chorionic villus biopsy and cordocentesis</div></td><td class="s1"></td></tr><tr style="height: 20px"><th id="1856240103R51" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">52</div></th><td class="s3 softmerge" dir="ltr"><div class="softmerge-inner" style="width:298px;left:-1px">APH and PV bleeding in pregnancy</div></td><td class="s1"></td></tr><tr style="height: 20px"><th id="1856240103R52" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">53</div></th><td class="s3 softmerge" dir="ltr"><div class="softmerge-inner" style="width:198px;left:-1px">External cephalic version</div></td><td class="s10"></td></tr><tr style="height: 20px"><th id="1856240103R53" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">54</div></th><td class="s3 softmerge" dir="ltr"><div class="softmerge-inner" style="width:198px;left:-1px">Abdominal trauma</div></td><td class="s10"></td></tr><tr style="height: 20px"><th id="1856240103R54" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">55</div></th><td class="s3 softmerge" dir="ltr"><div class="softmerge-inner" style="width:198px;left:-1px">Ectopic pregnancy</div></td><td class="s10"></td></tr><tr style="height: 20px"><th id="1856240103R55" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">56</div></th><td class="s3 softmerge" dir="ltr"><div class="softmerge-inner" style="width:198px;left:-1px">Evacuation of molar pregnancy</div></td><td class="s10"></td></tr><tr style="height: 20px"><th id="1856240103R56" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">57</div></th><td class="s3 softmerge" dir="ltr"><div class="softmerge-inner" style="width:198px;left:-1px">Intrauterine death and stillbirth</div></td><td class="s10"></td></tr><tr style="height: 20px"><th id="1856240103R57" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">58</div></th><td class="s3 softmerge" dir="ltr"><div class="softmerge-inner" style="width:498px;left:-1px">In-utero therapeutic interventions (transfusion, surgery, insertion of shunts, laser)</div></td><td class="s1"></td></tr><tr style="height: 20px"><th id="1856240103R58" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">59</div></th><td class="s3 softmerge" dir="ltr"><div class="softmerge-inner" style="width:298px;left:-1px">Miscarriage, threatened miscarriage</div></td><td class="s1"></td></tr><tr style="height: 20px"><th id="1856240103R59" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">60</div></th><td class="s3 softmerge" dir="ltr"><div class="softmerge-inner" style="width:298px;left:-1px">Therapeutic termination of pregnancy</div></td><td class="s1"></td></tr><tr style="height: 20px"><th id="1856240103R60" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">61</div></th><td class="s2" dir="ltr">Delivery</td><td></td></tr><tr style="height: 20px"><th id="1856240103R61" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">62</div></th><td class="s3 softmerge" dir="ltr"><div class="softmerge-inner" style="width:198px;left:-1px">Intra-operative cell salvage</div></td><td class="s10"></td></tr><tr style="height: 20px"><th id="1856240103R62" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">63</div></th><td class="s2" dir="ltr"></td><td class="s2" dir="ltr"></td></tr><tr style="height: 20px"><th id="1856240103R63" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">64</div></th><td class="s5" dir="ltr">Sources</td><td class="s2" dir="ltr"></td></tr><tr style="height: 20px"><th id="1856240103R64" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">65</div></th><td class="s2" dir="ltr">RCOG</td><td class="s11 softmerge" dir="ltr"><div class="softmerge-inner" style="width:598px;left:-1px"><a target="_blank" href="https://www.rcog.org.uk/globalassets/documents/guidelines/rbc_gtg65.pdf">The Management of Women with Red Cell Antibodies during Pregnancy – GTG No. 65 – May 2014</a></div></td></tr><tr style="height: 20px"><th id="1856240103R65" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">66</div></th><td class="s12 softmerge" dir="ltr"><div class="softmerge-inner" style="width:198px;left:-1px"><a target="_blank" href="https://www.rcog.org.uk/globalassets/documents/guidelines/rbc_gtg65.pdf">Red cell antibodies</a></div></td><td class="s7" dir="ltr"></td></tr></tbody></table></div>